Specialty Pharmacy

Guselkumab is a monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23.

Galcanezumab-gnlm (Emgality, Lilly) has received FDA-approval for the preventive treatment of migraine in adults and for the treatment of episodic cluster headache in adults.

Pembrolizumab (Keytruda, Merck) monotherapy approved for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high solid tumors.

The most common adverse reactions observed in the monarchE phase 3 trial include diarrhea, neutropenia, fatigue, infections, nausea, abdominal pain, vomiting, anemia, alopecia, decreased appetite, and leukopenia.

Lurbinectedin (Zepzelca) approved based on overall response rate and duration of response in patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy.

Although many hubs offer similar services, no two specialty pharmacy hubs and no two hub programs are entirely alike.

Facing MBC Together is intended to recognize the prevalence and impact of isolation on the lives of individuals with metastatic breast cancer.

Pre-conference workshops will be held on September 14, with the Annual Meeting & Expo sessions and events taking place over the next four days—September 15 through September 18.

The updated guidelines include increased recommended physical activity levels and a growing emphasis on holistic rather than nutrient-based dietary habits.

Inebilizumab-cdon is only the second approved treatment for neuromyelitis optica spectrum disorder, according to the FDA.

Pharmacists can play a role in the drug reimbursement process for oncology products, which are among the most expensive of all pharmaceuticals.

FDA officials based their approval on the review of data and evidence that demonstrated a close similarity between pegfilgrastim-apgf and its reference product.

Ripretinib is a kinase inhibitor indicated for adults with advanced GIST, approved by the FDA in May 2020.

Apalutamide in combination with ADT prolonged median OS by 14 months and decreased the risk of death by 22%. Further, median OS was significantly longer, with 73.9 months for patients receiving treatment with apalutamide in combination with ADT compared with 59.9 months for patients receiving placebo in combination with ADT.

Interventions such as exercise programs and discharge planning efforts have been promising in addressing functional impairment and improving post-discharge outcomes.

Tildrakizumab is an IL-23 inhibitor indicated for adults with moderate-to-severe plaque psoriasis and is under investigation for PsA.

According to a recent study, diet can affect the outcome of chemotherapy due to microbes in the gut that can trigger changes in a patient’s response to drugs.

In the new data cut-offs from both studies, the survival advantages for the combination with fulvestrant and combination with an aromatase inhibitor were shown, but major disadvantages were also evident, according to the IQWiG.

The COVID-19 pandemic rapidly pushed traditional face-to-face instruction within schools of pharmacy into a fully remote learning environment.

Mitapivat is an investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes that is not yet approved by the FDA.

With the evolution and growth of specialty pharmacies, so too did services provided by hubs and the places where they were situated.

IVLBCL is a rare subtype of lymphoma that is particularly hard to diagnose due to a lack of swelling or enlargement of the lymph nodes.

Investigators found that less than a quarter of study participants with colorectal cancer were taking their medications as prescribed, suggesting that many could benefit from improved adherence.

According to a recent study, olanzapine may help patients with advanced cancer manage symptoms unrelated to chemotherapy, such as nausea and vomiting.

Specialty pharmacy is beginning to implement its own set of strategies in order to manage the cost of one of the most expensive sectors of the pharmaceutical industry.

Telemedicine and connected devices are emerging as technologies to provide greater access and convenience to care for those who can defer treatment by way of an in-person consultation.

At the 2020 American Society of Clinical Oncology Virtual Scientific Program, researchers presented a recent study that is the largest to date analyzing CLL treatment patterns among VHA patients between 2013 and 2018.

Trastuzumab deruxtecan (T-DXd) (Enhertu) demonstrated strong efficacy in a phase 2 trial for treatment of HER2-positive metastatic breast cancer.

Treatment with avelumab (Bavencio) potentially cured 8 of 15 women in a trial with gestational trophoblastic tumors resistant to single-agent chemotherapy.

Ensuring patients continue receiving life-sustaining home infusions that were traditionally administered in the hospital or hospital clinic settings is of the upmost importance.